🇺🇸 FDA
Pipeline program

9-ING-41

HCC 22-194

Phase 2 small_molecule terminated

Quick answer

9-ING-41 for Pancreatic Adenocarcinoma is a Phase 2 program (small_molecule) at ACTUATE THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ACTUATE THERAPEUTICS, INC.
Indication
Pancreatic Adenocarcinoma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials